A neuropeptide antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Antagonist G (trifluoroacetate salt)

Item No. 34425

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-arginyl-D-tryptophyl-N-methyl-L-phenylalanyl-D-tryptophyl-L-leucyl-L-methioninamide, trifluoroacetate salt
Synonyms
  • Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH2
  • [Arg6,D-Trp7,9,NmePhe8]-Substance P (6-11)
  • [Arg6,D-Trp7,9,NmePhe8]-SP (6-11)
Molecular Formula
C49H66N12O6S • XCF3COOH
Formula Weight
951.2
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlDMSO:PBS (pH 7.2) (1:3): 0.25 mg/mlEthanol: 20 mg/ml
λmax
220 nm
SMILES
CSCC[C@@H](C(N)=O)NC([C@H](CC(C)C)NC([C@@H](CC1=CNC2=CC=CC=C12)NC([C@H](CC3=CC=CC=C3)N(C)C([C@H](NC([C@@H](N)CCCNC(N)=N)=O)CC4=CNC5=CC=CC=C45)=O)=O)=O)=O.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C49H66N12O6S.C2HF3O2/c1-29(2)23-39(45(64)57-38(43(51)62)20-22-68-4)58-46(65)40(25-31-27-55-36-18-10-8-15-33(31)36)59-47(66)42(24-30-13-6-5-7-14-30)61(3)48(67)41(26-32-28-56-37-19-11-9-16-34(32)37)60-44(63)35(50)17-12-21-54-49(52)53;3-2(4,5)1(6)7/h5-11,13-16,18-19,27-29,35,38-42,55-56H,12,17,20-26,50H2,1-4H3,(H2,51,62)(H,57,64)(H,58,65)(H,59,66)(H,60,63)(H4,52,53,54);(H,6,7)/t35-,38-,39-,40+,41+,42-;/m0./s1
InChi Key
GUDATFWCKFMCTO-RGVCNNQFSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $109

    Add

    5 mg

    $517

    Add

    10 mg

    $981

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Antagonist G is a neuropeptide antagonist.1,2,3 It inhibits the binding of vasopressin to rat liver or Swiss 3T3 membranes (IC50s = 3.5 and 2.2 µM, respectively) and vasopressin-induced production of inositol phosphate in Swiss 3T3 fibroblasts (IC50 = 1 µM).1 Antagonist G (50 µM) induces apoptosis and the production of reactive oxygen species (ROS) in NCI H69 small cell lung cancer (SCLC) cells.2 It reduces tumor growth in an NCI H69 mouse xenograft model when administered at a dose of 45 µg/g.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Seckl, M.J., Newman, R.H., Freemont, P.S., et al. Substance P-related antagonists inhibit vasopressin and bombesin but not 5'-3-O-(thio)triphosphate-stimulated inositol phosphate production in swiss 3T3 cells. J. Cell Physiol. 163(1), 87-95 (1995).

    2. MacKinnon, A.C., Waters, C., Rahman, I., et al. [Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) (antagonist G) induces AP-1 transcription and sensitizes cells to chemotherapy. Br. J. Cancer. 83(7), 941-948 (2000).

    3. Langdon, S., Sethi, T., Ritchie, A., et al. Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo. Cancer Res. 52(16), 4554-4557 (1992).